Interest of Molecular Analysis of Cerebral Thrombi in Determining the Prognosis and Etiology of Cerebral Infarction
- Conditions
- Ischemic Stroke
- Interventions
- Other: Thrombi and blood analyses
- Registration Number
- NCT05658835
- Lead Sponsor
- Assistance Publique Hopitaux De Marseille
- Brief Summary
The MATISSE (Molecular Analysis of Thrombus for Ischemic Stroke prognosis and Etiology) project evaluates the hypothesis that the molecular composition of cerebral thrombus in metabolites, lipids, and proteins conditions the clinical prognosis at 3 months of the infarction and informs on its etiological subtype
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 311
- Male or female 18 years of age or older;
- Patient with a cerebral infarction documented by brain imaging who received endovascular treatment by mechanical thrombectomy;
- Patient for whom it was possible to collect cerebral thrombus for LC-MS analysis during mechanical thrombectomy:
- Patient who was informed of the study and formulated a non-opposition to participation. If not, patient for whom a relative was informed and formulated a non-opposition.
- Patient with a cerebral infarction documented by cerebral imaging, having benefited from an endovascular treatment with mechanical thrombectomy that did not allow the extraction of a cerebral thrombus.
- Protected persons (articles L1121-5, L1121-6 and L121-8 of the Public Health Code): pregnant or breast-feeding women, persons deprived of liberty, under guardianship or curatorship
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Patient suffering from ischemic stroke Thrombi and blood analyses -
- Primary Outcome Measures
Name Time Method Determination and validation of molecular signatures, obtained by LC-MS analysis of cerebral thrombi, predictive of the excellent clinical prognosis 3 months after the cerebral infarction Rankin score (0 to 6, 6 meaning worse outcome)
- Secondary Outcome Measures
Name Time Method Death 3 months after cerebral infarction Death of the patient
Severe intracranial hemorrhage 3 months after the cerebral infarction Heildeberg classification (0 to 3d, 3d meaning subdural hemorrhage)
Use of thrombolytic therapy in the acute phase Before thrombectomy Quantification of thrombolytic therapy
Positive infarct growth after successful recanalization Between 24 and 48h after the thrombectomy Quantification of infarctus volume by MRI
Patient exposure to peak outdoor air pollution 96 hours before cerebral infarction Quantification of peak outdoor air pollution (identification of the location of the patient and the polluants observed in the areas)
Early Neurological Deterioration 24 hours after recanalization treatment Worsening of at least 4 points in the NIHSS (National Institutes of Health Stroke Scale) score (0 meaning better outcome, 0 to 42)
Determination and validation of molecular signatures, obtained by LC-MS analysis 3 months after the cerebral infarction ASCOD (atherosclerosis, small vessel disease (SVD), cardioembolism, other and dissection) description (0 to 9, 9 meaning insufficient assessment to determine the presence or absence of the disease)
Recovery of autonomy in walking 7 days after the cerebral infarction Parker score (0 to 9, 9 meaning better outcome)
Determination of molecular signatures predictive on successful recanalization after mechanical thrombectomy Right after the thrombectomy Score mTICI (modified Thrombolysis In Cerebral Infarction, 0 to 3, 0 meaning worst outcome)
Trial Locations
- Locations (4)
CHU Martinique
🇫🇷Fort-de-France, France
Stroke Center
🇫🇷Marseille, France
CHU Guadeloupe
🇫🇷Pointe-à -Pitre, France
CHU La Réunion
🇫🇷Saint-Pierre, France